Will You Use Stemless Implants in Your TSA Patients?
Two shoulder specialists – Dr. Frances Cuomo and Dr. Mark Frankle – offer their thoughts on this new type of implant for patients with shoulder osteoarthritis, only recently cleared for marketing by the FDA.
The pending introduction of a stemless implant for total shoulder arthroplasty (TSA) in the U.S. market (Simpliciti Shoulder System, Tornier, Edina, Minnesota) is intended to offer orthpaedic surgeons a new bone-sparing option for managing patients with severe shoulder joint pain, compromised range of motion, and loss of strength and functionality caused by osteoarthritis or traumatic arthritis.
The U.S. Food and Drug Administration cleared the implant for marketing earlier this year. Clinical trials in the U.S. are currently evaluating 2 additional stemless implants (Arthrex Eclipse, Arthrex, Naples, Florida; Biomet Nano, Biomet, Warsaw, Indiana).
Stemless implants for TSA have been in use in Europe only since the mid-2000s. According to a recently published article, short-term (2- to 3-year minimum follow-up) clinical results were similar to those achieved with traditional TSA implants.  The implant was stable on radiographic analysis, without migration or subsidence.  Mid- and long-term outcomes are still unknown.
Shortly before the Simpliciti Shoulder System was cleared by the FDA, we asked 2 shoulder specialists – Frances Cuomo, MD, from Beth Israel Medical Center, New York, New York, and Mark Frankle, MD, from the Florida Orthopaedic Institute, Tampa, Florida – for their thoughts on these implants, including whether they would use stemless implants in their shoulder practice.
Click on the image below to hear their comments.
Producer: Susan Doan-Johnson; Director and Post Production: Charles Maynard
- Churchill RS. Stemless shoulder arthroplasty: current status. Journal of Shoulder and Elbow Surgery. 2014;23(9):1409-14.